Jérémie LEFEVRE (MD, PhD) is professor of digestive surgery at Saint-Antoine Hospital in Paris (France) and specializes in colorectal surgery. He was nominated as Professor in 2015 at the age of 37 years old after a PhD on hereditary polyposis.
Prof Lefevre deals mainly with colorectal cancers, hereditary syndromes such as Lynch or polyposis and more complex affections such had anastomotic failure, recto-vaginal fistula, or IBD. He is the PI of several randomized trials for the GRECCAR group or the SAFE-3 trial an international (EU and USA) study with Patricia Sylla.
He has published more than 280 articles in peer-reviewed journals and has been invited to give more than 50 oral presentations at international meetings. He is a member of the GRECCAR board, general secretary of the French Society of Digestive Surgery, and has been nominated as a Young Leader of the French-American Foundation in 2017.
Selected publications from PubMed
Safety and Performance of the Colovac Anastomosis Protection Device. A Pooled Analysis of Prospective Studies Compared With Diverting Loop Ileostomy (SAFE-2025).
Sylla P, Lam K, Komen N, Tuech JJ, Spinelli A, Martz J, Rhee R, Marcet J, Cadière GB, Rouanet P, Karachun A, Denost Q, Sametdinov N, D'Hoore A, Lee S, Lefèvre JH
Ann Surg. 2026 Sep 2 doi: 10.1097/SLA.0000000000007171.
Safety and effectiveness of the Colovac anastomosis protection device compared with diverting ileostomy after low anterior resection: protocol for an international, multicentre, prospective, non-randomised comparative study (SAFE-3).
Pastier C, Sylla P, Lee SW, Spinelli A, Komen N, Marks J, Martz J, Rhee R, Maykel J, Marcet J, Denost Q, Zaghiyan K, Davids JS, Paluvoi N, Hiller D, McLemore EC, Maggiori L, D'hoore A, Jafari MD, Poylin V, Buzas CJ, Tuech JJ, Lefèvre JH
BMJ Open Gastroenterol. 2026 Jun 12;13(1) doi: 10.1136/bmjgast-2025-002235.
Risk factors associated with urinary tract infection within 4 days of male rectal cancer surgery in the era of enhanced recovery after surgery (ERAS) programs.
Faucheron JL, Tidadini F, Lakkis Z, Jafari M, Germain A, Rullier E, Lefevre J, Tuech JJ, Kartheuser A, Leonard D, Prudhomme M, Piessen G, Regimbeau JM, Cotte E, Duprez D, Badic B, Panis Y, Rivoire M, Meunier B, Portier G, Bosson JL, Vilotitch A, Foote A, Fischer J, Caspar Y, Rouanet P, Trilling B, GRECCAR study Group
Acta Chir Belg. 2026 Oct;126(5):188-194 doi: 10.1080/00015458.2026.2682162.
How do surgeons manage sigmoid volvulus electively? Results of a nationwide practice survey (AFC-SFCD-FRENCH).
Labiad C, Cazelles A, Fuks D, Lefèvre JH, Schwarz L, Bridoux V, Berdah S, Karoui M, Bajul M, Manceau G
Colorectal Dis. 2026 May;28(5):e70483 doi: 10.1111/codi.70483.
Disruptive Analysis of Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Clinical and Therapeutic Distinctions Between Low- and Mid-Rectal Cancers.
Noiret B, Perez RO, Conroy T, Brown CJ, Schrag D, Fernandez L, Lefevre JH, Benoist S, Rouanet P, Garcia-Aguilar J, Denost Q
J Clin Oncol. 2026 Apr 10;44(11):1016-1027 doi: 10.1200/JCO-25-01861.
Anastomotic leaks are among the most devastating complications in all forms of gastrointestinal surgery. The rates and adverse sequelae of anastomotic leaks are most common and potentially of the greatest detrimental impact at the two ends of the intestinal tract - the esophagus and the rectum. This program is the first one in a four-part series delving into every facet of anastomotic leaks in colorectal surgery practice. Bringing together 5 globally renowned experts, it addresses the incidence, financial, functional, and oncological costs of leaks. Dr. Antonio M. de Lacy, the founder of the AIS Channel, will demonstrate laparoscopic leak management. The program will conclude with a lively globally interactive panel discussion. Designed for every surgeon and surgical trainee involved in colorectal anastomosis, this program offers invaluable insights.
With Medtronic
Published
Apr 2024
During the European Society of Coloproctology (ESCP) meeting held in September in Berlin, Dr. Lefevre addressed the topic of the optimal waiting period between the end of the neoadjuvant treatment for rectal cancer and the surgery. Based on the data in the paper on the GRECCAR-6 trial published in 2016, the author gives an excellent background on the subject and expounds the findings of the trial in an attempt to cast light on the topic. In the GRECCAR-6 trial published in the Journal of Clinical Oncology i2016, the effect of neoadjuvant treatment at 7 weeks is compared to 11 weeks of waiting period in a multicenter, randomized, clinical trial. Patients had T3-T4N0 or N+ mid or low rectal cancer. The primary endpoint was to evaluate the rate of pathological complete response after neoadjuvant treatment. The study did not show any difference between both two groups in regards to the rate of pathological response after radiochemotherapy. The significant parameters found were a worse rate of complete mesorectum, and overall morbidity at 11 weeks. As expected, patients presenting with a complete pathological response had better oncological outcomes than the rest. In conclusions, waiting 11 weeks for surgery does not increase the rate of complete pathological response, and has no impact on tumoral characteristics or the overall survival rate when compared to a 7-week wait. [Image]
Published
Jan 2018
Help your network discover Dr. Jérémie Lefevre's clinical expertise.
